Resource Summary Report

Generated by dkNET on May 25, 2025

My Cancer Genome

RRID:SCR_004140
Type: Tool

Proper Citation

My Cancer Genome (RRID:SCR_004140)

Resource Information

URL: http://www.mycancergenome.org/

Proper Citation: My Cancer Genome (RRID:SCR_004140)

Description: A freely available online personalized cancer medicine knowledge resource for physicians, patients, caregivers and researchers that gives up-to-date information on what mutations make cancers grow and related therapeutic implications, including available clinical trials. It is a one-stop tool that matches tumor mutations to therapies, making information accessible and convenient for busy clinicians.

Abbreviations: MCG

Synonyms: MyCancerGenome.org

Resource Type: data or information resource, database

Defining Citation: PMID:32483629

Keywords: genome, disease, genome, medicine, clinical trial, mutation, therapy, FASEB list

Related Condition: Cancer, Tumor

Funding:

Resource Name: My Cancer Genome

Resource ID: SCR_004140

Alternate IDs: OMICS_01552

Record Creation Time: 20220129T080223+0000

Record Last Update: 20250525T032219+0000

Ratings and Alerts

No rating or validation information has been found for My Cancer Genome.

No alerts have been found for My Cancer Genome.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 90 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET.

Zhou J, et al. (2025) Circulating tumour DNA in predicting and monitoring survival of patients with locally advanced rectal cancer undergoing multimodal treatment: long-term results from a prospective multicenter study. EBioMedicine, 112, 105548.

Lutz S, et al. (2025) Unveiling the Digital Evolution of Molecular Tumor Boards. Targeted oncology, 20(1), 27.

Kratz JD, et al. (2024) The Epidemiology of Biliary Tract Cancer and Associated Prevalence of MDM2 Amplification: A Targeted Literature Review. Targeted oncology, 19(6), 833.

Png CW, et al. (2024) DUSP6 regulates Notch1 signalling in colorectal cancer. Nature communications, 15(1), 10087.

Pervushin NV, et al. (2024) BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition. Apoptosis : an international journal on programmed cell death, 29(11-12), 2197.

Kumar H, et al. (2024) FusionPDB: a knowledgebase of human fusion proteins. Nucleic acids research, 52(D1), D1289.

Gazola AA, et al. (2024) Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment. Molecular cytogenetics, 17(1), 28.

Schmidt A, et al. (2024) The p21CIP1-CDK4-DREAM axis is a master regulator of genotoxic stress-induced cellular senescence. Nucleic acids research, 52(12), 6945.

Stahler A, et al. (2024) Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212). Clinical cancer research : an official journal of the American Association for Cancer Research, 30(7), 1256.

Wu K, et al. (2023) Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs. NPJ precision oncology, 7(1), 8.

Brown M, et al. (2023) Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis. EMBO molecular medicine, 15(10), e17094.

Rae S, et al. (2023) Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders. Journal of cancer research and clinical oncology, 149(18), 16355.

Ade CM, et al. (2023) Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics. Journal for immunotherapy of cancer, 11(9).

Wu J, et al. (2023) Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC. Molecular oncology, 17(5), 810.

Winkelmann R, et al. (2022) Increased HRD score in cisplatin resistant penile cancer cells. BMC cancer, 22(1), 1352.

Sivapatham S, et al. (2022) Currently available molecular analyses for personalized tumor therapy (Review). Biomedical reports, 17(6), 95.

Reinhardt K, et al. (2022) PIK3CA-mutations in breast cancer. Breast cancer research and treatment, 196(3), 483.

Popat S, et al. (2022) Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG). The oncologist, 27(4), 255.

Yoon S, et al. (2022) Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. Cancer research and treatment, 54(1), 1.

Mafficini A, et al. (2022) Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants. Familial cancer, 21(4), 441.